Audit: QRS - Pyrrosia lingua for Health & Longevity

Audit conducted on 13/09/2026 07:45 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to an ER passage: protocol cells to ER lines 301/311/315, time cells to ER 338/360, benefits to ER 141–177, risks to ER 211–233, gates to ER 251–277, monitoring table to ER 390–400, qualitative list to ER 404–409, at-a-glance to ER 431–435.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Never demonstrated in people at any timepoint” (time_1_sub) and “reported in traditional practice only” (time_2_sub) carry the ER’s hedges from lines 360 and 388 unchanged.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute and interactions remain cautions, matching the ER’s split at lines 251–277; the null human result is retained in at_a_glance rather than softened.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Nothing from ER Benefit-Modifying Factors (180–192) or Risk-Modifying Factors (236–246) appears in any gate or risk tier; each QRS block draws only from its designated ER section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT IDs or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	The only attribution present, “Chinese Pharmacopoeia range 6–12 g” in action_1_sub, is attributed identically in the ER at line 301.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The QRS mirrors the ER’s sceptical, evidence-first register, reusing its own formulations (“rests on animals or test tubes”, “cheap, widely available”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric thresholds and named severity classes carry the expert register while plain-language glosses keep it accessible; the framing informs a decision rather than discouraging one.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as fact and range rather than instruction; no imperative verbs directed at a patient appear.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Gates and monitoring targets are presented as evidence-derived values, not as prescriptions; the footer disclaimer is intact.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised”, or “should” constructions appear in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns occur anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are glossed where used (e.g., “New York Heart Association Class III–IV (marked limitation or symptoms at rest)”, “Child-Pugh Class B or C (moderate to severe impairment)”).
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are stripped to the key fact; tier lists are semicolon-joined; monitoring “Why” cells are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes willingness to run baseline panels, 24-hour urine collections and cadmium testing, which presupposes exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, 24-hour urine collection and species-verified sourcing are presented without hedging on inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	The nine-marker monitoring panel and tiered evidence framing are not general-population material.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance leads with the evidence gap and the species-substitution problem — the two facts that actually govern a decision for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears only in the canonical topic; “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route and form are stated formally (“dried leaf simmered in water”, “topical two-herb preparation”); the lede’s “test tubes” and “cheap” are the ER’s own Conclusion wording (lines 431–435).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (QRS lines 445, 490, 539, 563, 580, 609, 627, 631–633, 769); tier labels “Low: “ and “Speculative: “ are unchanged.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names are present; the repeatable marker_#_* and qualitative_item_# slots are instantiated as marker_1–9 and qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full diff against the template shows changes confined to frontmatter values and variable payloads; the website="evidence_review", website="audit" and website="full_review" spans, all CSS, and the footer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	The only empty ER sections are the Benefits High/Medium and Risks High/Medium/Low tiers, which items 12.5 and 13.5 govern by requiring display:none rather than empty-state phrasing; no other source section is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard decoction dose”, “Best time of day”, “Single versus split dosing” and “Reassessment trigger” reproduce the ER bold labels at lines 301, 311, 315 and 338 exactly; monitoring row labels match the ER Biomarker column verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is shortened or reworded; the two time-to-effect cell labels split a single ER bullet whose two distinct facts have no separate bold labels in the source.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur in the file; the ER’s “⚠️ Conflicted” marker at line 141 was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every block is condensed to the minimum the completeness items allow: gate entries are single clauses, both tier lists are collapsed into one semicolon-joined <li>, monitoring “Why” cells are single clauses, and the cadence note is two sentences.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: the comment opens immediately after the doctype on line 1 and precedes all other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block is wholly enclosed in an HTML comment and no metadata value is echoed into any rendered element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values are trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: pyrrosia_lingua_2026-0913-0617_Opus_ER.md, matching the ER’s own filename frontmatter key.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the version badge at the head of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0913-0736, conforming to the required format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: pyrrosia_lingua_2026-0913-0617_Opus_QRS.html, matching the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including the tooling-added duration, git_user and git_issue; only the colon-bearing duration value is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Pyrrosia lingua for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Pyrrosia lingua for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/13/2026”, the correct reformat of 2026-0913-0736.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” line (ER line 30) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Four sentences distil the ER Conclusion (lines 431–435): traditional use, the null human result, the animal-only evidence base, and the sourcing problem that governs any purchase decision.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Two-thousand-year use and indications → ER 431; null urine chemistry → ER 433; “rests on animals or test tubes” → ER 433; cheap, available, shared trade name → ER 435.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms appear; “stone-forming urine chemistry” and “test tubes” replace the specialist alternatives.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“The one human ingestion study” is referenced without author, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result appears; the null finding is stated qualitatively as “found no change”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven entries map to the ER’s “Populations who should avoid Pyrrosia lingua” list and the lithium bullet, ER lines 253 and 269–277.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete one-to-one coverage of the ER’s seven avoid-populations, with lithium (ER line 253, “Absolute contraindication”) correctly promoted from the interaction list.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven discrete <li> elements at QRS lines 566–575.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER rationale clause is stripped (e.g., “— no reproductive toxicology exists for this fern in any species” and “where diuretic and electrolyte effects are least predictable”); no item carries a trailing dash clause.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Stage 4 or 5 with the under-30 mL/min/1.73 m² threshold, NYHA Class III–IV with its gloss, Child-Pugh B or C with its gloss, and the 135 mmol/L and 3.5 mmol/L cut-offs are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correspondingly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight entries map to the ER interaction bullets at lines 251–267.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight of the ER’s nine interaction bullets are carried; lithium is correctly excluded because it appears in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight discrete <li> elements at QRS lines 583–599.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution/Monitor” verdict, mechanism and monitoring instruction is stripped, and the Zhang et al. 2024 and Tian et al. 2016 citations are dropped; the ER’s “Other interventions —” prefix is removed from the sauna item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named example drugs survive: hydrochlorothiazide/chlorthalidone/furosemide, levofloxacin/ciprofloxacin, warfarin/tacrolimus/digoxin, ibuprofen/naproxen, spironolactone, and the five additive-diuretic supplements.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine such interactions, and the section is correspondingly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 301, 311 and 315.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and dose division are the three executable decisions in the ER protocol; the remaining bullets are sourcing commentary, pharmacokinetics and non-actionable population notes.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive ER-sourced content; no placeholder text remains anywhere in the panel.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Stone/bone onset in months and diuretic onset in hours to days come from ER line 360; the 8–12 week reassessment window comes from ER line 338. These are the only timing facts the ER states.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Set 1 attaches to the Low-tier stone benefit (ER 141), set 2 to the Speculative diuretic benefit (ER 155), set 3 to the cross-cutting reassessment window — correct descending order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-sourced content; each sub adds the ER’s own caveat rather than repeating the value.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at lines 338 and 360, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Both populated tiers map to ER Expected Benefits lines 139–177.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present at QRS lines 541–556 with the correct tier assignment.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER benefit headings are carried; the Magnitude paragraphs (1.5 g for seven days in 18 healthy men, 78 cases, 96% any-response rate) and all supporting narrative are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	“(Corneal Inflammation)” from the ER heading at line 147 is stripped; no parenthetical survives in either tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER High (line 133) and Medium (line 137) carry no benefits, and both spans are emptied and set to style="display: none" rather than carrying the ER’s explanatory sentences.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	The Speculative tier maps to ER lines 211–233.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present at QRS lines 611–621 with the correct tier assignment.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	All six ER risk headings are carried as bare noun phrases; the supporting paragraphs and the Li 2010, Xiao 2017, He 2024, Tian 2016 and Zhang 2015 citations are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears; the ER’s risk headings carry none, and none was imported from their bodies.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER High (line 201), Medium (line 205) and Low (line 207) carry no risks, and all three spans are emptied and set to style="display: none".

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success table at lines 390–400.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER rows are present in source order with targets transcribed exactly: eGFR ≥ 90, potassium 4.0–4.5, sodium 138–142, ALT ≤ 25/≤ 20, urine volume > 2.5 L, oxalate < 25 mg, calcium < 200/< 150 mg, citrate > 450/> 550 mg, cadmium < 0.5 µg/L.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 760–763 condense the ER narrative at line 388 into “Baseline, then 4 weeks, 12 weeks and every 6 months. 24-hour urine repeated at 12 weeks; cadmium at 6 months.”

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six entries map to the ER’s “Qualitative markers worth tracking alongside the labs” list at lines 404–409.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Complete six-for-six coverage — urinary comfort, night-time urination, cough and sputum character, energy and light-headedness on standing, anxiety or restlessness, digestive comfort — with each item’s trailing rationale clause trimmed.

Issues 13/09/2026 07:45

Pass rate 100.00%. No issues found.

Issues 13/09/2026 07:41

1. 4.5 — Sheet overruns one A4 page: With nine monitoring rows, a four-sentence cadence paragraph, six qualitative items, fifteen gate items and a six-line at-a-glance, the rendered sheet is roughly 1.7× the printable height of A4; the condensable surfaces were not condensed.
2. 14.3 — Cadence copied at ER length: monitoring_cadence (lines 760–765) carries the ER’s cadence passage nearly verbatim across four sentences instead of the compact schedule the one-page budget requires.

Fixes 13/09/2026 07:41

1. 14.3 — Monitoring cadence condensed: Reduced monitoring_cadence from four ER-length sentences to “Baseline, then 4 weeks, 12 weeks and every 6 months. 24-hour urine repeated at 12 weeks; cadmium at 6 months.”, keeping the full schedule while dropping the restated prose.
2. 4.5 — Qualitative items trimmed to markers: Stripped the trailing rationale clauses from all six qualitative items (e.g. “Digestive comfort, since the leaf is classified as cooling and is traditionally avoided in weak digestion” → “Digestive comfort”), collapsing nine rendered lines to six.
3. 4.5 — Interaction and time cells tightened: Shortened the additive-diuretic interaction item to “Additive diuretic or urine-alkalinising supplements (…)” with its named-herb list intact, and trimmed time_3_sub to “no delayed-onset effect described”.